跳至主要内容
临床试验/NCT00338273
NCT00338273撤回3 期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode

Otsuka Pharmaceutical Development & Commercialization, Inc.1 个研究点 分布在 1 个国家开始时间: 2006年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
撤回
试验地点
1
主要终点
Mean change from baseline to endpoint (Week 8 last observation carried forward = LOCF) on the Montgomery-Asberg Depression Rating Scale (MADRS) total score

研究概览

简要总结

The purpose of this study is to evaluate flexible doses (5-30 mg) of aripiprazole in patients with bipolar depression.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Outpatients
  • Must sign informed consent prior to protocol-related procedures

排除标准

  • Women who are pregnant, trying to become pregnant, or nursing
  • Significant risk of committing suicide
  • Any serious unstable medical conditions

研究组 & 干预措施

A1

Active Comparator

干预措施: Aripiprazole (Drug)

A2

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Mean change from baseline to endpoint (Week 8 last observation carried forward = LOCF) on the Montgomery-Asberg Depression Rating Scale (MADRS) total score

次要结局

  • Mean change from baseline to endpoint on the Clinical Global Impression-Bipolar Version, severity of illness score (depression)

研究者

研究点 (1)

Loading locations...

相似试验

A Study of Aripiprazole in Patients With Bipolar I... | 临床试验